liposarcoma

Summary

Summary: A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)

Top Publications

  1. Pilotti S, Lavarino C, Mezzelani A, Della Torre C, Minoletti F, Sozzi G, et al. Limited role of TP53 and TP53-related genes in myxoid liposarcoma. Tumori. 1998;84:571-7 pubmed
    Circumstantial evidence suggests that genetic changes may lead to tumor progression within the myxoid liposarcoma tumors (MLTs) carrying non-random chromosomal translocation t(12;16).
  2. Gobble R, Qin L, Brill E, Angeles C, Ugras S, O Connor R, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 2011;71:2697-705 pubmed publisher
    ..to liposarcomagenesis and serve as prognostic candidates, we undertook expression profiling of 140 primary liposarcoma samples, which were randomly split into training set (n = 95) and test set (n = 45)...
  3. Patil N, Abba M, Hödl P, Schwarzbach M, Allgayer H. A real time PCR based approach for the quantitative detection of FUS-CHOP fusion transcripts in human liposarcoma. Adv Med Sci. 2012;57:37-45 pubmed publisher
    Histology still forms the backbone for the diagnosis of the myxoid and round cell subtypes of liposarcoma but the molecular identification of the different transcript variants remains a challenge, due, in part, to the complexity of ..
  4. Hatanaka K, Yoshioka T, Tasaki T, Tanimoto A. Paratesticular dedifferentiated liposarcoma with leiomyosarcomatous differentiation: a case report with a review of literature. Diagn Pathol. 2013;8:142 pubmed publisher
    Paratesticular liposarcoma is a rare neoplasm, described in single case studies or components of larger studies, as histologically well-differentiated liposarcoma (WDL) and dedifferentiated liposarcoma (DL)...
  5. Pakos E, Gogou P, Apostolikas N, Batistatou A, Tsekeris P. Factors associated with outcome in liposarcomas of the extremities and trunk. J BUON. 2010;15:518-23 pubmed
    ..We aimed to evaluate the outcomes of patients with extremities and superficial trunk liposarcomas in relation to some clinicopathological factors...
  6. Zhang K, Chu K, Wu X, Gao H, Wang J, Yuan Y, et al. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 2013;73:1298-307 pubmed publisher
    ..we first comparatively examined the amplification and expression of FRS2 with CDK4 and MDM2 in dedifferentiated liposarcoma (DDLS) and undifferentiated high-grade pleomorphic sarcoma (UHGPS)...
  7. Smith K, Tran L, Tam B, Shurell E, Li Y, Braas D, et al. Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. Am J Pathol. 2013;182:1400-11 pubmed publisher
    b>Liposarcoma is a type of soft tissue sarcoma that exhibits poor survival and a high recurrence rate. Treatment is generally limited to surgery and radiation, which emphasizes the need for better understanding of this disease...
  8. Demetri G, Chawla S, von Mehren M, Ritch P, Baker L, Blay J, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188-96 pubmed publisher
    ..in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide...
  9. Manzia T, Gravante G, Toti L, Iaria G, Anselmo A, Fratoni S, et al. Management of spermatic cord liposarcoma in renal transplant recipients: case report. Transplant Proc. 2010;42:1355-7 pubmed publisher
    Herein, we report the case of a 52-year-old man with a spermatic cord liposarcoma that developed 4 years after renal transplantation. The patient was admitted with a diagnosis of inguinal hernia...

More Information

Publications72

  1. Tanas M, Goldblum J. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol. 2009;16:383-91 pubmed publisher
    ..Finally, we discuss the advantages and disadvantages of FISH as a technique when appraising soft tissue neoplasms...
  2. Wagner K, Benchetrit M, Bianchini L, Michiels J, Wagner N. Peroxisome proliferator-activated receptor ?/? (PPAR?/?) is highly expressed in liposarcoma and promotes migration and proliferation. J Pathol. 2011;224:575-88 pubmed publisher
    ..Thus, a potential use of PPAR? agonists for the treatment of liposarcoma had been suggested, but clinical trials failed to detect beneficial effects...
  3. Ray Coquard I, Blay J, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133-40 pubmed publisher
    We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection.
  4. Ugras S, Brill E, Jacobsen A, Hafner M, Socci N, DeCarolis P, et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res. 2011;71:5659-69 pubmed publisher
    b>Liposarcoma remains the most common mesenchymal cancer, with a mortality rate of 60% among patients with this disease...
  5. Fernández Ruiz M, Rodriguez Gil Y, Guerra Vales J, Manrique Municio A, Moreno Gonzalez E, Colina Ruizdelgado F. Primary retroperitoneal liposarcoma: clinical and histological analysis of ten cases. Gastroenterol Hepatol. 2010;33:370-6 pubmed publisher
    Retroperitoneal liposarcoma constitutes an uncommon and locally aggressive malignancy. We performed a retrospective analysis of 10 patients (6 males; mean age: 63...
  6. D Annibale M, Cosimelli M, Covello R, Stasi E. Liposarcoma of the colon presenting as an endoluminal mass. World J Surg Oncol. 2009;7:78 pubmed publisher
    b>Liposarcoma is one of the most common soft tissue sarcoma of adult life, usually occurring in the retroperitoneum and the extremities. Primary liposarcoma of the colon is very rare...
  7. Pehar M, Vukoja I, Rozic D, Miskovic J. Spontaneous diaphragmatic rupture related to local invasion by retroperitoneal liposarcoma. Ann R Coll Surg Engl. 2012;94:e18-9 pubmed publisher
    ..through the rupture site from within the retroperitoneum that was proven subsequently to be a dedifferentiated liposarcoma. Second surgery was performed to completely remove the liposarcoma tissue and repair a coincident old right ..
  8. Helias Rodzewicz Z, Pedeutour F, Coindre J, Terrier P, Aurias A. Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer. 2009;48:943-52 pubmed publisher
    ..These amplicons are either localized, in well-differentiated liposarcoma (WDLPS), on extrachromosomal structures (ring or rod chromosomes), or integrated into chromosome arms in ..
  9. De Nardi P, Bissolati M, Cristallo M, Staudacher C. Recurrent giant liposarcoma of the spermatic cord. Urology. 2012;79:113-4 pubmed publisher
    A giant recurrent retroperitoneal liposarcoma of the spermatic cord was removed in a 40-year-old man. The tumor measured 50 cm and weighed 42 Kilograms. Radiotherapy and chemotherapy have little role in this neoplasm...
  10. Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer. 2010;10:254 pubmed publisher
    ..Most cancers maintain telomeres by activating telomerase but a significant minority, mainly of mesenchymal origin, utilize an alternative lengthening of telomeres (ALT) mechanism...
  11. Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1? and enhances ?-catenin signaling. Cancer Res. 2012;72:1751-62 pubmed publisher
    b>Liposarcoma can be an aggressive, debilitating, and fatal malignancy. In this study, we identifed miRNAs associated with the differentiation status of liposarcoma to gain insight into the basis for its progression...
  12. Park J, Qin L, Prete F, Antonescu C, Brennan M, Singer S. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg. 2009;250:977-82 pubmed
    To identify the prognostic variables that predict disease-specific survival and second local recurrence-free survival in patients with recurrent retroperitoneal liposarcoma so as to guide clinical management.
  13. Sargos P, Dejean C, de Figueiredo B, Brouste V, Nguyen Bui B, Italiano A, et al. High-dose pre-operative helical tomotherapy (54 Gy) for retroperitoneal liposarcoma. Radiat Oncol. 2012;7:214 pubmed publisher
    ..To evaluate the feasibility of pre-operative radiotherapy (54 Gy) with Helical Tomotherapy (HT) followed by surgery...
  14. Papavdi A, Agapitos E. Undiagnosed primary cardiac liposarcoma in an adult: a case report and review of the literature. Am J Forensic Med Pathol. 2013;34:299-301 pubmed publisher
    ..A rare case of an undiagnosed, primary, well-differentiated cardiac liposarcoma is presented, in a 67-year-old man who suffered a sudden cardiac death...
  15. Brill E, Gobble R, Angeles C, Lagos Quintana M, Crago A, Laxa B, et al. ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res. 2010;70:6891-901 pubmed publisher
    ..Currently, the mainstay of therapy for liposarcoma is surgical excision because liposarcomas are often resistant to traditional chemotherapy...
  16. Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B, et al. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res. 2011;17:1796-806 pubmed publisher
    We previously reported that nelfinavir (NFV) induces G(1) cell-cycle block and apoptosis selectively in liposarcoma cell lines due to increased SREBP-1 (sterol regulatory element binding protein-1) expression in the absence of increased ..
  17. Erickson Johnson M, Seys A, Roth C, King A, Hulshizer R, Wang X, et al. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol. 2009;22:1541-7 pubmed publisher
    ..cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor...
  18. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere Vince D, Dumollard J, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696-703 pubmed publisher
    ..Our goal was to determine whether the absence of CDK4 amplification was (a) correlated to a specific clinico-histopathologic profile; and (b) compensated by another genomic anomaly involving the CCND1/CDK4/P16INK4a/RB1/E2F pathway...
  19. Louis Brennetot C, Coindre J, Ferreira C, Pérot G, Terrier P, Aurias A. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer. 2011;50:896-907 pubmed publisher
    ..present in almost all cases without CDK4 amplification, thereby confirming the pivotal role of this pathway in liposarcoma oncogenesis...
  20. Salemis N, Tsiambas E, Karameris A, Tsohataridis E. Giant retroperitoneal liposarcoma with mixed histological pattern: a rare presentation and literature review. J Gastrointest Cancer. 2009;40:138-41 pubmed publisher
    Retroperitoneal liposarcoma is a rare tumor that may grow to a considerable size before causing clinical symptoms. Mixed-type retroperitoneal liposarcoma is a very rare clinical entity.
  21. Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz Gurpide J, Pilotti S, et al. Other targetable sarcomas. Semin Oncol. 2009;36:358-71 pubmed publisher
    Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy...
  22. Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011;91:392-403 pubmed publisher
    Therapeutic progress in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) is hampered by lack of relevant experimental models, thereby limiting comprehensive molecularly based investigations...
  23. Nahal A, Meterissian S. Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol. 2009;32:353-5 pubmed publisher
    ..Sarcomas with dual fatty and smooth muscle differentiation are even rarer. The purpose of this paper is to discuss a rare presentation of a lipoleiomyosarcoma and review, the method of pathologic diagnosis and the literature...
  24. Jones A, Lewis C, Dildey P, Hide G, Ragbir M. Lipoma or liposarcoma? A cautionary case report. J Plast Reconstr Aesthet Surg. 2012;65:e11-4 pubmed publisher
    ..We describe a case in which a lipoma-like liposarcoma was identified following excision of what was expected, on clinical and radiological grounds, to be a lipoma...
  25. Campioli E, Batarseh A, Li J, Papadopoulos V. The endocrine disruptor mono-(2-ethylhexyl) phthalate affects the differentiation of human liposarcoma cells (SW 872). PLoS ONE. 2011;6:e28750 pubmed publisher
    ..These results suggest that TSPO can be considered an important player in the differentiation process itself, or alternatively a factor whose presence is essential for adipocyte development...
  26. Rodriguez R, Rubio R, Gutierrez Aranda I, Melen G, Elosua C, Garcia Castro J, et al. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells. 2011;29:179-92 pubmed publisher
    ..However, sarcoma models based on human MSCs are still missing. We attempted to develop a model of liposarcoma by expressing FUS (FUsed in Sarcoma; also termed TLS, Translocated in LipoSarcoma)-CHOP (C/EBP HOmologous ..
  27. García Morúa A, Lozano Salinas J, Valdés Sepúlveda F, Zapata H, Gómez Guerra L. [Liposarcoma of the espermatic cord: our experience and review of the literature]. Actas Urol Esp. 2009;33:811-5 pubmed
    ..The paratesticular tumors represent 7-10% of the intraescrotales masses. Sarcomas includes 90% of the espermatic cord malignant lessons and approximately the 3-7% are liposarcomas...
  28. Chung L, Lau S, Jiang Z, Loera S, Bedel V, Ji J, et al. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am J Surg Pathol. 2009;33:1594-600 pubmed publisher
    Dedifferentiated liposarcoma (DDL), occurring in up to 10% of well differentiated liposarcoma cases, has similar histologic features to that of undifferentiated high-grade pleomorphic sarcoma (UHGPS); the former develops in a background ..
  29. Huh W, Yuen C, Munsell M, Hayes Jordan A, Lazar A, Patel S, et al. Liposarcoma in children and young adults: a multi-institutional experience. Pediatr Blood Cancer. 2011;57:1142-6 pubmed publisher
    There are limited data regarding the differences in clinical presentation and outcome of liposarcomas between adult and pediatric patients. The role of adjuvant radiotherapy in the treatment of childhood liposarcoma is unclear.
  30. Gutierrez A, Snyder E, Mariño Enríquez A, Zhang Y, Sioletic S, Kozakewich E, et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011;108:16386-91 pubmed publisher
    Well-differentiated liposarcoma (WDLPS), one of the most common human sarcomas, is poorly responsive to radiation and chemotherapy, and the lack of animal models suitable for experimental analysis has seriously impeded functional ..
  31. Pan J, Mott M, Xi B, Hepner E, Guan M, Fousek K, et al. Phase I study of nelfinavir in liposarcoma. Cancer Chemother Pharmacol. 2012;70:791-9 pubmed publisher
    ..HIV protease inhibitors are associated with HIV protease inhibitor-related lipodystrophy syndrome. We hypothesized that liposarcomas would be similarly susceptible to the apoptotic effects of an HIV protease inhibitor, nelfinavir...
  32. Crago A, Socci N, Decarolis P, O Connor R, Taylor B, Qin L, et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012;18:1334-40 pubmed publisher
    Molecular events underlying progression of well-differentiated liposarcoma (WDLS) to dedifferentiated liposarcoma (DDLS) are poorly defined...
  33. Aleixo P, Hartmann A, Menezes I, Meurer R, Oliveira A. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009;62:1127-35 pubmed publisher
    ..MDM2 and CDK4 protein overexpression have also been identified in these tumours...
  34. Hoffman A, Ghadimi M, Demicco E, Creighton C, Torres K, Colombo C, et al. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013;119:1868-77 pubmed publisher
    Myxoid liposarcoma (MLPS), a disease especially of young adults with potential for local recurrence and metastasis, currently lacks solid prognostic factors and therapeutic targets...
  35. Coindre J, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010;456:167-79 pubmed publisher
    Atypical lipomatous tumor or well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) share the same basic genetic abnormality characterized by a simple genomic profile with a 12q14-15 amplification involving ..
  36. Dickson M, Tap W, Keohan M, D Angelo S, Gounder M, Antonescu C, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31:2024-8 pubmed publisher
    ..In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS...
  37. Gits C, van Kuijk P, Jonkers M, Boersma A, Smid M, Van Ijcken W, et al. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer. 2014;135:348-61 pubmed publisher
    ..More insight into the biology of liposarcoma tumorigenesis is needed to devise novel therapeutic approaches...
  38. Gardner J, Dandekar M, Thomas D, Goldblum J, Weiss S, Billings S, et al. Cutaneous and subcutaneous pleomorphic liposarcoma: a clinicopathologic study of 29 cases with evaluation of MDM2 gene amplification in 26. Am J Surg Pathol. 2012;36:1047-51 pubmed publisher
    Pleomorphic liposarcoma (PL) is an uncommon form of liposarcoma that rarely occurs in the skin and subcutis...
  39. Thway K, Robertson D, Thway Y, Fisher C. Dedifferentiated liposarcoma with meningothelial-like whorls, metaplastic bone formation, and CDK4, MDM2, and p16 expression: a morphologic and immunohistochemical study. Am J Surg Pathol. 2011;35:356-63 pubmed publisher
    We studied 5 cases of dedifferentiated liposarcoma with meningothelial-like whorls and metaplastic bone formation, assessing morphology and immunohistochemical expression of a panel of antigens (CDK4, MDM2, and p16 proteins, desmin, ..
  40. Wang L, Wang L, Gu Y, Shu Y, Shen Y, Xu Q. Integrin ?6(high) cell population functions as an initiator in tumorigenesis and relapse of human liposarcoma. Mol Cancer Ther. 2011;10:2276-86 pubmed publisher
    The relapse and resistance to chemo- and radiotherapy are main problems in the treatment of human liposarcoma. It is important to find a functional marker existing in the liposarcoma cells for targeting...
  41. Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, et al. Establishment and characterization of a novel dedifferentiated liposarcoma cell line, NDDLS-1. Pathol Int. 2011;61:461-8 pubmed publisher
    We established a dedifferentiated liposarcoma cell line (NDDLS-1) that produces interleukin-6 (IL-6) and granulocyte-colony stimulating factor (G-CSF). The parental tumor showed high leukemoid reactions...
  42. Snyder E, Sandstrom D, Law K, Fiore C, Sicinska E, Brito J, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009;218:292-300 pubmed publisher
    ..kinases have been implicated as a mechanism of progression from well-differentiated to dedifferentiated liposarcoma. To further define the role of c-Jun in liposarcoma progression, we performed immunohistochemistry for c-Jun ..
  43. Song J, Gardner J, Tarrant W, Shen S, Ayala A, Yu E, et al. Dedifferentiated liposarcoma with peculiar meningothelial-like whorling and metaplastic bone formation. Ann Diagn Pathol. 2009;13:278-84 pubmed publisher
    Dedifferentiated liposarcoma with peculiar meningothelial-like whorling pattern and metaplastic bone formation (DDLMB) is an unusual morphologic entity that is characterized by an atypical lipomatous tumor/well-differentiated liposarcoma ..
  44. Rieker R, Weitz J, Lehner B, Egerer G, Mueller A, Kasper B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch. 2010;456:277-85 pubmed publisher
    ..These data indicate that dedifferentiated LS follow separate tumourigenic pathways and that genetic analysis is important to unravel these differences...
  45. Lucas D, Shukla A, Thomas D, Patel R, Kubat A, McHugh J. Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features. Am J Surg Pathol. 2010;34:844-51 pubmed publisher
    The dedifferentiated component of dedifferentiated liposarcoma shows wide histologic variation including tumors with heterologous differentiation. Myofibroblastic differentiation has been recognized in dedifferentiated liposarcoma...
  46. Mitomi M, Kimura K, Iguchi Y, Hayashida A, Nishimura H, Irei I, et al. A case of stroke due to tumor emboli associated with metastatic cardiac liposarcoma. Intern Med. 2011;50:1489-91 pubmed
    Cardioembolic stroke due to tumor emboli is a rare complication of neoplasm. A patient with metastatic cardiac liposarcoma who suffered from embolic stroke is reported...
  47. Kim Y, Leem D, Baek J, Ko S. Atypical lipomatous tumor/well-differentiated liposarcoma of the gingiva: a case report and review of literature. J Oral Maxillofac Surg. 2014;72:431-9 pubmed publisher
    b>Liposarcoma, first described by Virchow in 1857, is a common mesenchymal malignant tumor arising from the adipose tissue. The most common of all soft tissue sarcomas, liposarcomas account for approximately 20% of all soft tissue sarcomas...
  48. Fernandez F, García H. [Giant dedifferenciated liposarcoma of the spermatic cord]. Arch Esp Urol. 2009;62:751-5 pubmed
    To describe a patient with dedifferentiated liposarcoma of the spermatic cord and to perform a bibliographic review.
  49. Gupta R, Sharma A, Arora R, Kulkarni M, Chattopadhaya T, Singh M. Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer. 2010;41:79-83 pubmed publisher
    Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature. Incomplete resection of the tumor leads to recurrence, and recurrent tumors carry a risk of dedifferentiation...
  50. de Vreeze R, de Jong D, Nederlof P, Ariaens A, Tielen I, Frenken L, et al. Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Ann Surg Oncol. 2010;17:686-93 pubmed publisher
    Treatment decisions and prognosis assessment for liposarcoma is based on a classification that depends on morphological and genetic features. Revisions by experienced referral pathologists are often advocated.
  51. Olsen A, Eisenberg B, Kuemmerle N, Flanagan A, Morganelli P, Lombardo P, et al. Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol. 2010;36:1309-14 pubmed
    ..These findings warrant further studies aimed at the clinical exploitation of the dependence of LS cell growth on fatty acids...
  52. Tan C, Dasari B, Smyth J, Brown R. Liposarcoma of the spermatic cord: a report of two cases. Ann R Coll Surg Engl. 2012;94:e10-2 pubmed publisher
    ..Careful clinical and radiological examination will help in appropriate preoperative planning and surgery by an experienced surgical team. We report our experience of two cases of such scrotal swellings...
  53. Weaver J, Rao P, Goldblum J, Joyce M, Turner S, Lazar A, et al. Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?. Mod Pathol. 2010;23:1301-6 pubmed publisher
    Well-differentiated liposarcoma/atypical lipomatous tumor can be difficult to differentiate from benign lipomatous tumors, especially on limited biopsy material...
  54. Hisaoka M, Matsuyama A, Nakamoto M. Aberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcoma. Am J Pathol. 2012;180:2076-83 pubmed publisher
    ..gene expression profiling study identified several unique genes that were highly expressed in dedifferentiated liposarcoma, and the gene encoding calreticulin (CALR), a major Ca(2+)-buffering protein that can inhibit adipocyte ..
  55. Mariño Enríquez A, Fletcher C, Dal Cin P, Hornick J. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol. 2010;34:1122-31 pubmed publisher
    Dedifferentiated liposarcoma (LPS) is a malignant adipocytic neoplasm defined as the transition from well-differentiated LPS to a nonlipogenic sarcoma...
  56. Kinebuchi Y, Ishizuka O, Minagawa T, Nisizawa O, Shimojo H. [Concurrent perirenal liposarcoma associated with renal cell carcinoma]. Hinyokika Kiyo. 2009;55:571-4 pubmed
    Here, we present a case of concurrent perirenal liposarcoma associated with renal cell carcinoma (RCC) in a 60-year-old man. The tumor was detected by ultrasonography, computed tomography and magnetic resonance imaging...
  57. Kim H, Lee J, Yi S, Jun H, Choi Y, Ahn G, et al. Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer. 2009;9:205 pubmed publisher
    Prognosis and optimal treatment strategies of liposarcoma have not been fully defined. The purpose of this study is to define the distinctive clinical features of liposarcomas by assessing prognostic factors.
  58. Spitzer J, Ugras S, Runge S, Decarolis P, Antonescu C, Tuschl T, et al. mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes Cancer. 2011;50:338-47 pubmed publisher
    ..We thus investigated whether the loss of one FUS allele by translocation in liposarcoma may be followed by mutations in either the remaining FUS allele or the paralogous EWSR1...
  59. O Regan K, Jagannathan J, Krajewski K, Zukotynski K, Souza F, Wagner A, et al. Imaging of liposarcoma: classification, patterns of tumor recurrence, and response to treatment. AJR Am J Roentgenol. 2011;197:W37-43 pubmed publisher
    The purpose of this study was to illustrate the subtypes of liposarcoma (LPS) and the significance of the nonlipomatous tumor components using multiple imaging modalities.
  60. Horvai A, Devries S, Roy R, O Donnell R, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-88 pubmed publisher
    b>Liposarcoma represents a unique model insofar as some well-differentiated liposarcomas progress to non-lipogenic, so-called 'dedifferentiated,' forms...
  61. Mahmood S, Agresta S, Vigil C, Zhao X, Han G, D Amato G, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129:1963-9 pubmed publisher
    ..Patients with documented unresectable or metastatic STS (liposarcoma, leiomyosarcoma and malignant fibrous histiocytoma [MFH]), measurable disease, and 3 or less prior lines of ..
  62. Mariño Enríquez A, Hornick J, Dal Cin P, Cibas E, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014;122:128-37 pubmed publisher
    Dedifferentiated liposarcoma (DDLPS) and pleomorphic liposarcoma (PLPS) are distinct high-grade liposarcomas. DDLPS is a nonlipogenic sarcoma characterized by amplification of MDM2 and CDK4...
  63. Wanchick K, Lucha P. Dedifferentiated retroperitoneal liposarcoma presenting as lower gastrointestinal bleeding, a case report and review of the literature. Mil Med. 2009;174:328-30 pubmed
    ..The incidence is 2.5 per million and liposarcoma accounts for approximately 20% of all retroperitoneal sarcomas...